These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28560582)

  • 1. Towards standardization of
    Unterrainer M; Vettermann F; Brendel M; Holzgreve A; Lifschitz M; Zähringer M; Suchorska B; Wenter V; Illigens BM; Bartenstein P; Albert NL
    EJNMMI Res; 2017 Dec; 7(1):48. PubMed ID: 28560582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel semiautomated method for background activity and biological tumour volume definition to improve standardisation of
    Brighi C; Puttick S; Li S; Keall P; Neville K; Waddington D; Bourgeat P; Gillman A; Fay M
    EJNMMI Phys; 2022 Feb; 9(1):9. PubMed ID: 35122529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-label CNN model for the automatic detection and segmentation of gliomas using [
    Rahimpour M; Boellaard R; Jentjens S; Deckers W; Goffin K; Koole M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2441-2452. PubMed ID: 36933075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches.
    Holzgreve A; Brendel M; Gu S; Carlsen J; Mille E; Böning G; Mastrella G; Unterrainer M; Gildehaus FJ; Rominger A; Bartenstein P; Kälin RE; Glass R; Albert NL
    Front Neurosci; 2016; 10():260. PubMed ID: 27378835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods.
    Rausch I; Zitterl A; Berroterán-Infante N; Rischka L; Prayer D; Fenchel M; Sareshgi RA; Haug AR; Hacker M; Beyer T; Traub-Weidinger T
    Eur Radiol; 2019 Aug; 29(8):4276-4285. PubMed ID: 30635757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of blood-brain barrier permeability on O-(2-
    Stegmayr C; Bandelow U; Oliveira D; Lohmann P; Willuweit A; Filss C; Galldiks N; Lübke JH; Shah NJ; Ermert J; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):408-416. PubMed ID: 27613541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool.
    Lopez WO; Cordeiro JG; Albicker U; Doostkam S; Nikkhah G; Kirch RD; Trippel M; Reithmeier T
    Onco Targets Ther; 2015; 8():3803-15. PubMed ID: 26719708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.
    Albert NL; Winkelmann I; Suchorska B; Wenter V; Schmid-Tannwald C; Mille E; Todica A; Brendel M; Tonn JC; Bartenstein P; la Fougère C
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1105-14. PubMed ID: 26666239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
    Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
    J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of region-of-interest determination on measurement of signal-to-noise ratio in liver on PET images.
    Amakusa S; Matsuoka K; Kawano M; Hasegawa K; Ouchida M; Date A; Yoshida T; Sasaki M
    Ann Nucl Med; 2018 Jan; 32(1):1-6. PubMed ID: 29058224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Unterrainer M; Galldiks N; Suchorska B; Kowalew LC; Wenter V; Schmid-Tannwald C; Niyazi M; Bartenstein P; Langen KJ; Albert NL
    J Nucl Med; 2017 Apr; 58(4):584-589. PubMed ID: 27754904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients.
    Gutsche R; Scheins J; Kocher M; Bousabarah K; Fink GR; Shah NJ; Langen KJ; Galldiks N; Lohmann P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
    Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
    J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.